T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Aclaris Therapeutics
ACRS
$860M
| $470K | ﹤0.01% |
32,343
-399
| -1% | -$6.04K |
|
|
PGRE
2402
DELISTED
Paramount Group
PGRE
| $470K | ﹤0.01% |
56,349
-68,007
| -55% | -$603K |
|
2403
Photronics
PLAB
$1.97B
| $470K | ﹤0.01% |
24,908
-1,097
| -4% | -$16.1K |
|
2404
Kforce
KFRC
$1.03B
| $469K | ﹤0.01% |
6,232
-310
| -5% | -$22.3K |
|
|
AAT
2405
American Assets Trust
AAT
$1.39B
| $467K | ﹤0.01% |
12,446
-761
| -6% | -$28.6K |
|
2406
Agilysys
AGYS
$3.03B
| $467K | ﹤0.01% |
10,504
-304
| -3% | -$14.4K |
|
|
RDUS
2407
DELISTED
Radius Recycling
RDUS
| $465K | ﹤0.01% |
8,951
-1,458
| -14% | -$74.8K |
|
|
ZUO
2408
DELISTED
Zuora, Inc.
ZUO
| $465K | ﹤0.01% |
+24,891
| New | +$500K |
|
|
TSP
2409
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $465K | ﹤0.01% |
+12,958
| New | +$483K |
|
|
ENDP
2410
DELISTED
Endo International plc
ENDP
| $465K | ﹤0.01% |
123,756
-86,675
| -41% | -$420K |
|
|
PR
2411
Permian Resources
PR
$18B
| $464K | ﹤0.01% |
77,516
-13,260
| -15% | -$90.3K |
|
2412
Albertsons Companies
ACI
$5.83B
| $461K | ﹤0.01% |
15,266
+6,175
| +68% | +$196K |
|
|
CVGW
2413
DELISTED
Calavo Growers
CVGW
| $459K | ﹤0.01% |
+10,830
| New | +$443K |
|
|
KBAL
2414
DELISTED
Kimball International
KBAL
| $458K | ﹤0.01% |
44,797
-700
| -2% | -$7.57K |
|
|
TRTX
2415
TPG RE Finance Trust
TRTX
$610M
| $457K | ﹤0.01% |
37,097
-972
| -3% | -$12.4K |
|
|
WSR
2416
DELISTED
Whitestone REIT
WSR
| $457K | ﹤0.01% |
45,140
-4,853
| -10% | -$47.3K |
|
2417
Acushnet Holdings
GOLF
$5.2B
| $455K | ﹤0.01% |
8,573
-2,172
| -20% | -$114K |
|
2418
Rio Tinto
RIO
$160B
| $455K | ﹤0.01% |
6,804
| – | – |
|
|
ANAT
2419
DELISTED
American National Group, Inc. Common Stock
ANAT
| $455K | ﹤0.01% |
2,410
+282
| +13% | +$53.4K |
|
2420
Theravance Biopharma
TBPH
$878M
| $454K | ﹤0.01% |
41,061
-9,500
| -19% | -$82.8K |
|
|
VSTO
2421
DELISTED
Vista Outdoor Inc.
VSTO
| $452K | ﹤0.01% |
9,803
-915
| -9% | -$39.1K |
|
2422
Quanex
NX
$1B
| $451K | ﹤0.01% |
18,214
+2,800
| +18% | +$62.5K |
|
2423
Veeco
VECO
$3.26B
| $451K | ﹤0.01% |
15,857
-839
| -5% | -$21.4K |
|
|
BCOV
2424
DELISTED
Brightcove, Inc.
BCOV
| $451K | ﹤0.01% |
44,166
+18,600
| +73% | +$196K |
|
|
ONIT
2425
Onity Group
ONIT
$321M
| $449K | ﹤0.01% |
11,224
+2,151
| +24% | +$72.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.